Search results for "hepatology"

showing 10 items of 2737 documents

Steatohepatitis and type 2 diabetes mellitus are influenced by genetic susceptibility to increased intestinal permeability in patients with non-alcoh…

2017

medicine.medical_specialtyIntestinal permeabilityHepatologybusiness.industrySettore MED/12 - GASTROENTEROLOGIAFatty liverGastroenterologyType 2 Diabetes MellitusNon alcoholicDiseasemedicine.diseaseGastroenterologyN/AInternal medicinemedicineGenetic predispositionIn patientSteatohepatitisbusinessDigestive and Liver Disease
researchProduct

Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation

2014

medicine.medical_specialtyKidneyHepatologyRe transplantationbusiness.industryGastroenterologyMEDLINEHepatitis Cmedicine.diseaseGastroenterologychemistry.chemical_compoundmedicine.anatomical_structurePharmacotherapychemistryInternal medicineBoceprevirmedicinebusinessViral loadKidney transplantationDigestive and Liver Disease
researchProduct

Non-alcoholic fatty liver disease pathogenesis: The present and the future

2008

Non-alcoholic fatty liver disease is the clinical hepatic expression of metabolic syndrome. The prevalence of non-alcoholic fatty liver disease is around 20-30%, and with a rapid increase in the metabolic risk factors in the general population, non-alcoholic fatty liver disease has become the most common cause of liver disease worldwide. A fraction (20-30%) of non-alcoholic fatty liver disease patients develop a potentially progressive hepatic disorder, namely non-alcoholic steatohepatitis, leading to end-stage liver disease. The pathogenesis of non-alcoholic fatty liver disease is not entirely understood, and even if insulin resistance is a major pathogenetic key, many other factors are im…

medicine.medical_specialtyLipolysisPopulationPhysiologyApoptosisMitochondria LiverInsulin resistance Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis SteatosisDiseaseFatty Acids NonesterifiedPathogenesisLiver diseaseInsulin resistanceAdipokinesRisk FactorsInternal medicinemedicineAnimalsHumansGenetic Predisposition to Diseaseeducationeducation.field_of_studyHepatologybusiness.industryFatty liverGastroenterologymedicine.diseaseDietFatty LiverOxidative StressEndocrinologyAdipose TissueLiverDisease ProgressionHepatocytesCytokinesInsulin ResistanceSteatohepatitisMetabolic syndromebusinessDigestive and Liver Disease
researchProduct

Guinea pig Kupffer cells can be activated in vitro to an enhanced superoxide response

1988

Summary In the preceding paper it was shown that Kupffer cells isolated by digestion of the liver and purified by centrifugal elutriation can be activated in vitro by lipopolysaccharide and muramyl dipeptide to an enhanced superoxide response upon zymosan phagocytosis. Lipopolysaccharide and muramyl dipeptide also led to a strongly increased prostaglandin E 2 release during the phagocytosis of zymosan. This activation was accompanied by an increased production of prostaglandin E 2 during the incubation with the stimuli. Prostaglandin E 2 synthesis was inhibited by the cyclooxygenase inhibitor indomethacin, reduced by dexamethasone, but only slightly decreased by the lipoxygenase inhibitor n…

medicine.medical_specialtyLipopolysaccharidemedicine.medical_treatmentPhagocytosisPronaseBiologyLipoxygenasechemistry.chemical_compoundInternal medicinemedicineHepatologySuperoxideZymosanMolecular biologyIn vitroNordihydroguaiaretic acidEndocrinologymedicine.anatomical_structurechemistryBiochemistryHepatocytebiology.proteinlipids (amino acids peptides and proteins)CyclooxygenaseMuramyl dipeptideProstaglandin EJournal of Hepatology
researchProduct

Evidence-based medicine and the problem of healthy volunteers

2017

Abstract Healthy controls are subjects without the disease being studied but may have other conditions indirectly affecting outcome. In the present epidemics of obesity a few subjects with undiagnosed nonalcoholic fatty liver disease enter clinical studies as controls, producing biased results. Stricter selection criteria should be considered to prevent this risk.

medicine.medical_specialtyLiver EnzymesSpecialties of internal medicinePredictive Value of TestDiseaseGastroenterology03 medical and health sciences0302 clinical medicineClinical trialsLiver Function TestsPredictive Value of TestsReference ValuesNon-alcoholic Fatty Liver DiseaseLiver enzymeInternal medicineNAFLDHealthy volunteersNonalcoholic fatty liver diseasemedicineHumansReference ValueObesitySelection (genetic algorithm)Evidence-Based MedicineHepatologybusiness.industryLiver Function TestPatient SelectionLiver enzymeControl groupGeneral MedicineEvidence-based medicineClinical trials. Control group. Liver Enzymes. NAFLD. Obesitymedicine.diseaseObesityHealthy VolunteerHealthy VolunteersClinical trialClinical trialRC581-951030211 gastroenterology & hepatologybusiness030217 neurology & neurosurgeryHuman
researchProduct

The role of insulin-like growth factor II in the malignant transformation of rat liver oval cells

1997

Oval cells are small nonparenchymal epithelial cells that first appear in the periportal areas of the liver and thereafter invade the whole parenchyma when mice or rats are exposed to a variety of chemical carcinogens. In the present study we have analyzed the expression of insulin-like growth factor II (IGF II) in the recently established oval cell line OC/CDE 22 and its malignantly transformed counterpart (the M22 cells) and the biological consequences of the constitutive expression of IGF II in oval cells. OC/CDE 22 cells do not express the above-mentioned growth factor, whereas the M22 cells do and addition of a neutralizing anti-IGF II antibody to M22 cells resulted in an almost comple…

medicine.medical_specialtyLiver cytologymedicine.medical_treatmentBiologyCell LineMalignant transformationMiceLiver Neoplasms ExperimentalGrowth factor receptorInsulin-Like Growth Factor IINeutralization TestsInternal medicinemedicineAnimalsAutocrine signallingHepatologyGrowth factorEpithelial CellsOncogenesTransfectionMolecular biologyRatsCell Transformation NeoplasticEndocrinologyLiverCell cultureInsulin-like growth factor 2biology.proteinMitogensHepatology
researchProduct

Forecasting liver disease burden

2018

medicine.medical_specialtyLiver diseaseHepatologybusiness.industryGastroenterologymedicineIntensive care medicinemedicine.diseasebusinessDigestive and Liver Disease
researchProduct

Surgery in patients with liver disease

1999

medicine.medical_specialtyLiver diseaseHepatologybusiness.industrymedicineIn patientmedicine.diseasebusinessSurgeryHepatology
researchProduct

Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?

2019

Contrast-enhanced ultrasound (CEUS) represents a significant breakthrough in ultrasonography (US), and it is being increasingly used for the evaluation of focal liver lesions (FLLs). CEUS is unique in that it allows non-invasively assessment of liver perfusion in real time throughout the vascular phase, which has led to dramatic improvements in the diagnostic accuracy of US in the detection and characterization of FLLs, the choice of therapeutic procedures, and the evaluation of response. Currently, CEUS is included as a part of the suggested diagnostic work-up of FLLs, including in cirrhotic patients with hepatocellular carcinoma, resulting in better patient management and cost-effective d…

medicine.medical_specialtyLiver perfusionlcsh:Medical technologyHepatocellular carcinomaDiagnostic accuracyReview Article030218 nuclear medicine & medical imagingUltrasound contrast mediaLiver cirrhosi03 medical and health sciences0302 clinical medicinemedicineContrast-enhanced ultrasonographyRadiology Nuclear Medicine and imagingUltrasound contrast mediaUltrasonographybusiness.industryUltrasoundmedicine.diseasePatient managementlcsh:R855-855.5LiverHepatocellular carcinomaLiver cirrhosis030211 gastroenterology & hepatologyRadiologyUltrasonographybusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaContrast-enhanced ultrasoundUltrasonography
researchProduct

Clinical course of ulcerative colitis

2008

. Dig Liver Dis. 2008 Jul;40 Suppl 2:S247-52. Clinical course of ulcerative colitis. Cottone M, Scimeca D, Mocciaro F, Civitavecchia G, Perricone G, Orlando A. Department of Medicine, Pneumology and Nutrition Clinic, V. Cervello Hospital, University of Palermo, Palermo, Italy. AIM: To provide a review of studies on prognosis in ulcerative colitis by reviewing the relevant population-based cohort studies. On the basis of incidence and population studies, ulcerative colitis has a favourable clinical course, with good quality of life, a chronic course characterized by at least one relapse, and a surgery rate of 30% after 10 years from diagnosis. Patients affected by severe ulcerative colitis h…

medicine.medical_specialtyLymphomaColorectal cancermedicine.medical_treatmentPopulationSeverity of Illness IndexGastroenterologyRisk FactorsInternal medicinemedicineHumansColitiseducationColectomyColectomyeducation.field_of_studyHepatologybusiness.industryMortality rateGastroenterologyCase-control studyPrognosismedicine.diseaseUlcerative colitisCase-Control StudiesColonic NeoplasmsColitis UlcerativeSteroidsbusinessulcerative colittis.clinical course.Immunosuppressive AgentsCohort study
researchProduct